Neurogene Completes Dosing in Registrational Trial for Rett Syndrome Gene Therapy NGN-401
NGNE sits 81% above its 52-week low of $14.65.
Summary
Neurogene Inc. announced the successful completion of dosing in its Embolden registrational trial for NGN-401, its lead gene therapy candidate for Rett syndrome, exceeding its enrollment target.
Key Events · Product Development and Regulatory · NGNE
-
Registrational Trial Dosing Completed
Neurogene Inc. has successfully completed dosing in its Embolden registrational trial of NGN-401 for Rett syndrome, enrolling a total of 25 participants, exceeding the initial target of 20 due to strong community demand.
-
Positive Safety Profile Maintained
NGN-401 at the 1E15 vg dose continues to be generally well-tolerated, with no cases of hemophagocytic lymphohistiocytosis (HLH) reported in either the Phase 1/2 or Embolden trials.
-
Key Data Readouts Anticipated
The company expects to present updated interim safety and efficacy data from the Phase 1/2 trial in mid-2026, with topline data from the Embolden registrational trial anticipated in the second half of 2027.
Analysis · NGNE · Life Sciences
Neurogene Inc. has completed dosing in its Embolden registrational trial for NGN-401, a gene therapy for Rett syndrome. This is a critical de-risking milestone, moving the company closer to a potential Biologics License Application (BLA) submission. The trial exceeded its enrollment target due to strong demand, and the therapy continues to show a generally well-tolerated safety profile with no cases of HLH at the 1E15 vg dose. Investors will now focus on the upcoming interim Phase 1/2 data expected mid-2026 and the topline data from the Embolden trial anticipated in the second half of 2027.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NGNE was trading at $26.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $418.6M. The 52-week trading range was $14.65 to $37.27. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.